Tags

Type your tag names separated by a space and hit enter

Aliskiren: an oral renin inhibitor for the treatment of hypertension.
Cardiol Rev. 2007 Nov-Dec; 15(6):316-23.CR

Abstract

Hypertension is a common chronic disease that leads to significant cardiovascular morbidity and mortality worldwide. Blood pressure control is critical in reducing the end-organ complications, such as stroke, myocardial infarction, heart failure, or kidney disease. Currently available antihypertensive agents work by different mechanisms to reduce blood pressure. Aliskiren, a novel direct renin inhibitor, lowers blood pressure by decreasing renin activity, and angiotensin I and II levels. At the approved dosage (150-300 mg once daily), it reduces systolic blood pressure by 12-16 mm Hg and diastolic blood pressure by 2-12 mm Hg. In studies its efficacy was comparable to losartan 100 mg, irbesartan 150 mg, and valsartan 80-320 mg. When used adjunctively with ramipril, an angiotensin-converting enzyme (ACE) inhibitor, valsartan, an angiotensin II receptor blocker (ARB), or hydrochlorothiazide, a diuretic, it provides additional blood pressure reduction compared with placebo or monotherapy. Aliskiren is well tolerated, with the most common side effects being gastrointestinal symptoms, fatigue, weakness, and headache. In short-term clinical trials, aliskiren caused fewer disturbances in potassium levels when compared with hydrochlorothiazide, ACE inhibitors and ARBs. Long-term data on morbidity and mortality outcomes are not currently available, thus it is unknown whether aliskiren would join ACE inhibitors and ARBs as the preferred hypertensive agents for end organ protection. At this time, aliskiren should be considered as an alternative agent for mild-to-moderate hypertension, or as an adjunctive therapy when preferred agents fail to maintain optimal blood pressure control. It is also an option for those patients who have contraindications or intolerability to other antihypertensive agents, including dry cough induced by ACE inhibitors.

Authors+Show Affiliations

Department of Clinical Pharmacy Practice, College of Pharmacy and Allied Health Professions, St. John's University, Jamaica, New York 11439, USA. Lams1@stjohns.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18090068

Citation

Lam, Sum, and Mary Choy. "Aliskiren: an Oral Renin Inhibitor for the Treatment of Hypertension." Cardiology in Review, vol. 15, no. 6, 2007, pp. 316-23.
Lam S, Choy M. Aliskiren: an oral renin inhibitor for the treatment of hypertension. Cardiol Rev. 2007;15(6):316-23.
Lam, S., & Choy, M. (2007). Aliskiren: an oral renin inhibitor for the treatment of hypertension. Cardiology in Review, 15(6), 316-23.
Lam S, Choy M. Aliskiren: an Oral Renin Inhibitor for the Treatment of Hypertension. Cardiol Rev. 2007 Nov-Dec;15(6):316-23. PubMed PMID: 18090068.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aliskiren: an oral renin inhibitor for the treatment of hypertension. AU - Lam,Sum, AU - Choy,Mary, PY - 2007/12/20/pubmed PY - 2008/1/10/medline PY - 2007/12/20/entrez SP - 316 EP - 23 JF - Cardiology in review JO - Cardiol Rev VL - 15 IS - 6 N2 - Hypertension is a common chronic disease that leads to significant cardiovascular morbidity and mortality worldwide. Blood pressure control is critical in reducing the end-organ complications, such as stroke, myocardial infarction, heart failure, or kidney disease. Currently available antihypertensive agents work by different mechanisms to reduce blood pressure. Aliskiren, a novel direct renin inhibitor, lowers blood pressure by decreasing renin activity, and angiotensin I and II levels. At the approved dosage (150-300 mg once daily), it reduces systolic blood pressure by 12-16 mm Hg and diastolic blood pressure by 2-12 mm Hg. In studies its efficacy was comparable to losartan 100 mg, irbesartan 150 mg, and valsartan 80-320 mg. When used adjunctively with ramipril, an angiotensin-converting enzyme (ACE) inhibitor, valsartan, an angiotensin II receptor blocker (ARB), or hydrochlorothiazide, a diuretic, it provides additional blood pressure reduction compared with placebo or monotherapy. Aliskiren is well tolerated, with the most common side effects being gastrointestinal symptoms, fatigue, weakness, and headache. In short-term clinical trials, aliskiren caused fewer disturbances in potassium levels when compared with hydrochlorothiazide, ACE inhibitors and ARBs. Long-term data on morbidity and mortality outcomes are not currently available, thus it is unknown whether aliskiren would join ACE inhibitors and ARBs as the preferred hypertensive agents for end organ protection. At this time, aliskiren should be considered as an alternative agent for mild-to-moderate hypertension, or as an adjunctive therapy when preferred agents fail to maintain optimal blood pressure control. It is also an option for those patients who have contraindications or intolerability to other antihypertensive agents, including dry cough induced by ACE inhibitors. SN - 1538-4683 UR - https://www.unboundmedicine.com/medline/citation/18090068/Aliskiren:_an_oral_renin_inhibitor_for_the_treatment_of_hypertension_ L2 - https://doi.org/10.1097/CRD.0b013e31814852a4 DB - PRIME DP - Unbound Medicine ER -